logo
Plus   Neg
Share
Email

Celgene: MM-003 Meets Primary Endpoint Of Improvement In PFS - Quick Facts

Celgene Corp.'s (CELG) unit, Celgene International Sàrl, reported phase III study data MM-003 of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination. MM-003 met the primary endpoint of improvement in progression-free survival or PFS.

PFS was significantly longer in patients who received pomalidomide plus low-dose dexamethasone compared with those who received high-dose dexamethasone.

According to the study design, an interim analysis of overall survival was conducted. During this analysis, pomalidomide plus low-dose dexamethasone demonstrated a highly statistically significant improvement in overall survival that crossed the upper boundary for superiority. Consequently, the Data Monitoring Committee urged that patients who had not yet progressed in the high-dose dexamethasone arm should be crossed over to pomalidomide plus low-dose dexamethasone.

A Marketing Authorisation Application for pomalidomide combined with low-dose dexamethasone was submitted to the EMA in May 2012, and Celgene expects a decision by European regulatory authorities in the second half of 2013. Further, a new drug application has been accepted for review by the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act date of Feb. 10, 2013.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a signing ceremony for a bill rolling back regulations on small and medium-sized banks, President Donald Trump suggested Thursday he would also consider cutting regulations on larger financial institutions. Trump claimed complex and costly regulations implemented following the 2008 financial crisis... Shares of Hong Kong-listed Samsonite International S.A., the world's biggest luggage maker, tumbled almost 10 percent in Thursday's trading after a short seller issued a report saying that the company suffered from questionable accounting practices and poor corporate governance. Trading in Samsonite's shares were halted after the report was released. In a move likely to add to concerns about the possibility of a global trade war, the Commerce Department has initiated an investigation into whether imports of automobiles and parts threaten to impair U.S. national security. Commerce Secretary Wilbur Ross launched the investigation under Section 232...
Follow RTT